Nkarta (NKTX) Announces Positive Preliminary Dose Finding Data for Two Lead Engineered Natural Killer Cell Programs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
Nkarta (NKTX) Announces $150M Proposed Public Offering of Common Stock
April 25, 2022 4:01 PM EDTNkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, today announced that it has commenced a proposed underwritten public offering to issue and sell $150 million of shares of its common stock. The Company also intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of shares of its common stock on the same terms and conditions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may... More
Nkarta (NKTX) Halted Again on Volatility, Up 113%
April 25, 2022 11:54 AM EDTNkarta (NASDAQ: NKTX) Halted Again on Volatility, Up 113%
... MoreNkarta (NKTX) Halted on Volatility, Up 113%
April 25, 2022 10:12 AM EDTNkarta (NASDAQ: NKTX) Halted on Volatility, Up 113%
Nkarta (NKTX) Surges 55% After Announcing Positive Preliminary Dose Finding Data for Two Lead Engineered Natural Killer Cell Programs
April 25, 2022 7:12 AM EDTNkarta (NASDAQ: NKTX) Surges 55% After Announcing Positive Preliminary Dose Finding Data for Two Lead Engineered Natural Killer Cell Programs
... More